{
    "abstract": "Background Conserved pneumococcal proteins are potential candidates for inclusion in vaccines against pneumococcal diseases. In the first part of a two-part study, an investigational vaccine (PHiD-CV/dPly/PhtD-30) containing 10 pneumococcal serotype-specific polysaccharide conjugates (10VT) combined with pneumolysin toxoid and pneumococcal histidine triad protein D (30\u00a0\u03bcg each) was well tolerated by Gambian children. Part two, presented here, assessed the efficacy of two PHiD-CV/dPly/PhtD formulations against pneumococcal nasopharyngeal carriage (NPC) prevalence in infants. Methods In this phase 2, randomized, controlled, observer-blind trial, healthy infants aged 8\u201310\u00a0weeks, recruited from a peri-urban health center, were randomized (1:1:1:1:1:1) into six groups. Four groups received PHiD-CV/dPly/PhtD (10 or 30\u00a0\u03bcg of each protein), PHiD-CV, or 13-valent pneumococcal conjugate vaccine at ages 2\u20133\u20134\u00a0months (3\u00a0+\u00a00 infant schedule) and two groups PHiD-CV/dPly/PhtD-30 or PHiD-CV at 2\u20134\u20139\u00a0months (2\u00a0+\u00a01 infant schedule). The primary objective was impact on non-10VT NPC at ages 5\u20139\u201312\u00a0months. Secondary objectives included confirmatory analysis of protein dose superiority and safety/reactogenicity. Impact on pneumococcal NPC acquisition, bacterial load, and ply and phtD gene sequencing were explored. Results 1200 infants were enrolled between June 2011 and May 2012. Prevalences of pneumococcal (60\u201367%) and non-10VT (55\u201361%) NPC were high at baseline. Across all post-vaccination time points, efficacy of PHiD-CV/dPly/PhtD-10 and PHiD-CV/dPly/PhtD-30 against non-10VT NPC (3\u00a0+\u00a00 schedule) was 1.1% (95% CI \u221221.5, 19.5) and 2.1% (\u221220.3, 20.3), respectively; efficacy of PHiD-CV/dPly/PhtD-30 (2\u00a0+\u00a01 schedule) was 0.5% (\u221222.1, 18.9) versus PHiD-CV. No differences were observed in pneumococcal NPC acquisition, clearance, or bacterial load. Both protein-based vaccines elicited immune responses to pneumococcal proteins. Conclusions In this high carriage prevalence setting, inclusion of pneumococcal proteins in the PHiD-CV/dPly/PhtD investigational vaccine had no impact on pneumococcal NPC in infants, regardless of protein dose or schedule. Future evaluations will assess its impact against pneumococcal disease endpoints. Funding: PATH, GlaxoSmithKline Biologicals SA. ClinicalTrials.gov identifier NCT01262872.",
    "author_highlights": [
        {
            "endOffset": 21552,
            "sentence": "Pneumococcal protein antigens could provide serotype-independent protection.",
            "startOffset": 21476
        },
        {
            "endOffset": 21629,
            "sentence": "Two PHiD-CV/dPly/PhtD vaccine formulations were assessed in healthy infants.",
            "startOffset": 21553
        },
        {
            "endOffset": 21709,
            "sentence": "Both protein-based vaccines elicited immune responses to pneumococcal proteins.",
            "startOffset": 21630
        },
        {
            "endOffset": 21788,
            "sentence": "The vaccines had no impact on pneumococcal nasopharyngeal carriage prevalence.",
            "startOffset": 21710
        },
        {
            "endOffset": 21872,
            "sentence": "Future evaluations will assess their impact against pneumococcal disease endpoints.",
            "startOffset": 21789
        }
    ],
    "bib_entries": {
        "b0005": {
            "authors": [],
            "firstpage": "129",
            "issn": "00498114",
            "lastpage": "144",
            "pmid": "24340399",
            "pub_year": 2012,
            "title": "Pneumococcal vaccines WHO position paper--2012.",
            "volume": "87"
        },
        "b0010": {
            "authors": [
                {
                    "first": "V. T.",
                    "initial": "V.T.",
                    "last": "Devine"
                },
                {
                    "first": "J. M.",
                    "initial": "J.M.",
                    "last": "Jefferies"
                },
                {
                    "first": "S. C.",
                    "initial": "S.C.",
                    "last": "Clarke"
                },
                {
                    "first": "S. N.",
                    "initial": "S.N.",
                    "last": "Faust"
                }
            ],
            "doi": "10.1155/2015/394368",
            "issn": "23148861",
            "pmid": "26351646",
            "pub_year": 2015,
            "title": "Nasopharyngeal bacterial carriage in the conjugate vaccine era with a focus on pneumococci",
            "volume": "2015"
        },
        "b0015": {
            "authors": [
                {
                    "first": "Mark R.",
                    "initial": "M.R.",
                    "last": "Alderson"
                }
            ],
            "doi": "10.1016/j.vaccine.2016.03.107",
            "firstpage": "2959",
            "issn": "0264410X",
            "lastpage": "2961",
            "pmid": "27083428",
            "pub_year": 2016,
            "title": "Status of research and development of pediatric vaccines for Streptococcus pneumoniae",
            "volume": "34"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Anna",
                    "initial": "A.",
                    "last": "Roca"
                },
                {
                    "first": "Abdoulie",
                    "initial": "A.",
                    "last": "Bojang"
                },
                {
                    "first": "Christian",
                    "initial": "C.",
                    "last": "Bottomley"
                },
                {
                    "first": "Rebecca A.",
                    "initial": "R.A.",
                    "last": "Gladstone"
                },
                {
                    "first": "Jane U.",
                    "initial": "J.U.",
                    "last": "Adetifa"
                },
                {
                    "first": "Uzochukwu",
                    "initial": "U.",
                    "last": "Egere"
                },
                {
                    "first": "Sarah",
                    "initial": "S.",
                    "last": "Burr"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "Antonio"
                },
                {
                    "first": "Stephen",
                    "initial": "S.",
                    "last": "Bentley"
                },
                {
                    "first": "Beate",
                    "initial": "B.",
                    "last": "Kampmann"
                },
                {
                    "first": "Claire",
                    "initial": "C.",
                    "last": "Oluwalana"
                },
                {
                    "first": "Olubukola",
                    "initial": "O.",
                    "last": "Idoko"
                },
                {
                    "first": "Isatou",
                    "initial": "I.",
                    "last": "Cox"
                },
                {
                    "first": "Brenda A.",
                    "initial": "B.A.",
                    "last": "Kwambana-Adams"
                },
                {
                    "first": "Sheikh",
                    "initial": "S.",
                    "last": "Jarju"
                },
                {
                    "first": "Ebenezer",
                    "initial": "E.",
                    "last": "Foster-Nyarko"
                },
                {
                    "first": "Brian",
                    "initial": "B.",
                    "last": "Greenwood"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1016/j.vaccine.2015.11.012",
            "firstpage": "7144",
            "issn": "0264410X",
            "lastpage": "7151",
            "pmid": "26592141",
            "pub_year": 2015,
            "title": "Effect on nasopharyngeal pneumococcal carriage of replacing PCV7 with PCV13 in the Expanded Programme of Immunization in The Gambia",
            "volume": "33"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Grant A.",
                    "initial": "G.A.",
                    "last": "Mackenzie"
                },
                {
                    "first": "Philip C.",
                    "initial": "P.C.",
                    "last": "Hill"
                },
                {
                    "first": "David J.",
                    "initial": "D.J.",
                    "last": "Jeffries"
                },
                {
                    "first": "Ilias",
                    "initial": "I.",
                    "last": "Hossain"
                },
                {
                    "first": "Uchendu",
                    "initial": "U.",
                    "last": "Uchendu"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Ameh"
                },
                {
                    "first": "Malick",
                    "initial": "M.",
                    "last": "Ndiaye"
                },
                {
                    "first": "Oyedeji",
                    "initial": "O.",
                    "last": "Adeyemi"
                },
                {
                    "first": "Jayani",
                    "initial": "J.",
                    "last": "Pathirana"
                },
                {
                    "first": "Yekini",
                    "initial": "Y.",
                    "last": "Olatunji"
                },
                {
                    "first": "Bade",
                    "initial": "B.",
                    "last": "Abatan"
                },
                {
                    "first": "Bilquees S.",
                    "initial": "B.S.",
                    "last": "Muhammad"
                },
                {
                    "first": "Augustin E.",
                    "initial": "A.E.",
                    "last": "Fombah"
                },
                {
                    "first": "Debasish",
                    "initial": "D.",
                    "last": "Saha"
                },
                {
                    "first": "Ian",
                    "initial": "I.",
                    "last": "Plumb"
                },
                {
                    "first": "Aliu",
                    "initial": "A.",
                    "last": "Akano"
                },
                {
                    "first": "Bernard",
                    "initial": "B.",
                    "last": "Ebruke"
                },
                {
                    "first": "Readon C.",
                    "initial": "R.C.",
                    "last": "Ideh"
                },
                {
                    "first": "Bankole",
                    "initial": "B.",
                    "last": "Kuti"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Githua"
                },
                {
                    "first": "Emmanuel",
                    "initial": "E.",
                    "last": "Olutunde"
                },
                {
                    "first": "Ogochukwu",
                    "initial": "O.",
                    "last": "Ofordile"
                },
                {
                    "first": "Edward",
                    "initial": "E.",
                    "last": "Green"
                },
                {
                    "first": "Effua",
                    "initial": "E.",
                    "last": "Usuf"
                },
                {
                    "first": "Henry",
                    "initial": "H.",
                    "last": "Badji"
                },
                {
                    "first": "Usman N.A.",
                    "initial": "U.N.A.",
                    "last": "Ikumapayi"
                },
                {
                    "first": "Ahmad",
                    "initial": "A.",
                    "last": "Manjang"
                },
                {
                    "first": "Rasheed",
                    "initial": "R.",
                    "last": "Salaudeen"
                },
                {
                    "first": "E. David",
                    "initial": "E.D.",
                    "last": "Nsekpong"
                },
                {
                    "first": "Sheikh",
                    "initial": "S.",
                    "last": "Jarju"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "Antonio"
                },
                {
                    "first": "Sana",
                    "initial": "S.",
                    "last": "Sambou"
                },
                {
                    "first": "Lamin",
                    "initial": "L.",
                    "last": "Ceesay"
                },
                {
                    "first": "Yamundow",
                    "initial": "Y.",
                    "last": "Lowe-Jallow"
                },
                {
                    "first": "Momodou",
                    "initial": "M.",
                    "last": "Jasseh"
                },
                {
                    "first": "Kim",
                    "initial": "K.",
                    "last": "Mulholland"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Knoll"
                },
                {
                    "first": "Orin S.",
                    "initial": "O.S.",
                    "last": "Levine"
                },
                {
                    "first": "Stephen R.",
                    "initial": "S.R.",
                    "last": "Howie"
                },
                {
                    "first": "Richard A.",
                    "initial": "R.A.",
                    "last": "Adegbola"
                },
                {
                    "first": "Brian M.",
                    "initial": "B.M.",
                    "last": "Greenwood"
                },
                {
                    "first": "Tumani",
                    "initial": "T.",
                    "last": "Corrah"
                }
            ],
            "doi": "10.1016/S1473-3099(16)00054-2",
            "firstpage": "703",
            "issn": "14733099",
            "lastpage": "711",
            "pmid": "26897105",
            "pub_year": 2016,
            "title": "Effect of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in The Gambia: a population-based surveillance study",
            "volume": "16"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Stephanie M.",
                    "initial": "S.M.",
                    "last": "Davis"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Deloria-Knoll"
                },
                {
                    "first": "Hilina T.",
                    "initial": "H.T.",
                    "last": "Kassa"
                },
                {
                    "first": "Katherine L.",
                    "initial": "K.L.",
                    "last": "O'Brien"
                }
            ],
            "doi": "10.1016/j.vaccine.2013.05.005",
            "firstpage": "133",
            "issn": "0264410X",
            "lastpage": "145",
            "pmid": "23684824",
            "pub_year": 2013,
            "title": "Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: Review of evidence on indirect effects",
            "volume": "32"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Daniel M.",
                    "initial": "D.M.",
                    "last": "Weinberger"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Malley"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Lipsitch"
                }
            ],
            "doi": "10.1016/S0140-6736(10)62225-8",
            "firstpage": "1962",
            "issn": "01406736",
            "lastpage": "1973",
            "pmid": "21492929",
            "pub_year": 2011,
            "title": "Serotype replacement in disease after pneumococcal vaccination",
            "volume": "378"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Monica",
                    "initial": "M.",
                    "last": "Bologa"
                },
                {
                    "first": "Thierry",
                    "initial": "T.",
                    "last": "Kamtchoua"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Hopfer"
                },
                {
                    "first": "Xiaohua",
                    "initial": "X.",
                    "last": "Sheng"
                },
                {
                    "first": "Bryony",
                    "initial": "B.",
                    "last": "Hicks"
                },
                {
                    "first": "Garvin",
                    "initial": "G.",
                    "last": "Bixler"
                },
                {
                    "first": "Victor",
                    "initial": "V.",
                    "last": "Hou"
                },
                {
                    "first": "Vildana",
                    "initial": "V.",
                    "last": "Pehlic"
                },
                {
                    "first": "Tao",
                    "initial": "T.",
                    "last": "Yuan"
                },
                {
                    "first": "Sanjay",
                    "initial": "S.",
                    "last": "Gurunathan"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.10.076",
            "firstpage": "7461",
            "issn": "0264410X",
            "lastpage": "7468",
            "pmid": "23123106",
            "pub_year": 2012,
            "title": "Safety and immunogenicity of pneumococcal protein vaccine candidates: Monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine",
            "volume": "30"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Thierry",
                    "initial": "T.",
                    "last": "Kamtchoua"
                },
                {
                    "first": "Monica",
                    "initial": "M.",
                    "last": "Bologa"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Hopfer"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Neveu"
                },
                {
                    "first": "Branda",
                    "initial": "B.",
                    "last": "Hu"
                },
                {
                    "first": "Xiaohua",
                    "initial": "X.",
                    "last": "Sheng"
                },
                {
                    "first": "Nicolas",
                    "initial": "N.",
                    "last": "Corde"
                },
                {
                    "first": "Catherine",
                    "initial": "C.",
                    "last": "Pouzet"
                },
                {
                    "first": "Gloria",
                    "initial": "G.",
                    "last": "Zimmermann"
                },
                {
                    "first": "Sanjay",
                    "initial": "S.",
                    "last": "Gurunathan"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.11.005",
            "firstpage": "327",
            "issn": "0264410X",
            "lastpage": "333",
            "pmid": "23153437",
            "pub_year": 2013,
            "title": "Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults",
            "volume": "31"
        },
        "b0050": {
            "authors": [
                {
                    "first": "W. Abdullah",
                    "initial": "W.A.",
                    "last": "Brooks"
                },
                {
                    "first": "Lee Jah",
                    "initial": "L.J.",
                    "last": "Chang"
                },
                {
                    "first": "Xiaohua",
                    "initial": "X.",
                    "last": "Sheng"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Hopfer"
                },
                {
                    "first": "Guy",
                    "initial": "G.",
                    "last": "de Bruyn"
                },
                {
                    "first": "Monica",
                    "initial": "M.",
                    "last": "Bologa"
                },
                {
                    "first": "Josemund",
                    "initial": "J.",
                    "last": "Menezes"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Kirby"
                },
                {
                    "first": "Xavier",
                    "initial": "X.",
                    "last": "Da Costa"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Neveu"
                },
                {
                    "first": "Sanjay",
                    "initial": "S.",
                    "last": "Gurunathan"
                },
                {
                    "first": "Doli",
                    "initial": "D.",
                    "last": "Goswami"
                },
                {
                    "first": "Sultana",
                    "initial": "S.",
                    "last": "Yeasmin"
                },
                {
                    "first": "Nasrin",
                    "initial": "N.",
                    "last": "Parvin"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": "Moshtaq Ahmed"
                },
                {
                    "first": "Kamrun",
                    "initial": "K.",
                    "last": "Nahar"
                },
                {
                    "first": "Mohammed Ziaur",
                    "initial": "M.Z.",
                    "last": "Rahman"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1016/j.vaccine.2015.06.078",
            "firstpage": "4610",
            "issn": "0264410X",
            "lastpage": "4617",
            "pmid": "26143615",
            "pub_year": 2015,
            "title": "Safety and immunogenicity of a trivalent recombinant PcpA, PhtD, and PlyD1 pneumococcal protein vaccine in adults, toddlers, and infants: A phase I randomized controlled study",
            "volume": "33"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Geert",
                    "initial": "G.",
                    "last": "Leroux-Roels"
                },
                {
                    "first": "Cathy",
                    "initial": "C.",
                    "last": "Maes"
                },
                {
                    "first": "Fien",
                    "initial": "F.",
                    "last": "De Boever"
                },
                {
                    "first": "Magali",
                    "initial": "M.",
                    "last": "Traskine"
                },
                {
                    "first": "Jens U.",
                    "initial": "J.U.",
                    "last": "R\u00fcggeberg"
                },
                {
                    "first": "Dorota",
                    "initial": "D.",
                    "last": "Borys"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.02.052",
            "firstpage": "6838",
            "issn": "0264410X",
            "lastpage": "6846",
            "pmid": "24607003",
            "pub_year": 2014,
            "title": "Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: A phase I/II randomized clinical study",
            "volume": "32"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Prymula"
                },
                {
                    "first": "Petr",
                    "initial": "P.",
                    "last": "Pazdiora"
                },
                {
                    "first": "Magali",
                    "initial": "M.",
                    "last": "Traskine"
                },
                {
                    "first": "Jens U.",
                    "initial": "J.U.",
                    "last": "R\u00fcggeberg"
                },
                {
                    "first": "Dorota",
                    "initial": "D.",
                    "last": "Borys"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.03.066",
            "firstpage": "3025",
            "issn": "0264410X",
            "lastpage": "3034",
            "pmid": "24699466",
            "pub_year": 2014,
            "title": "Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: A phase II randomized clinical trial",
            "volume": "32"
        },
        "b0065": {
            "authors": [
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Odutola"
                },
                {
                    "first": "M. O.",
                    "initial": "M.O.",
                    "last": "Ota"
                },
                {
                    "first": "E. O.",
                    "initial": "E.O.",
                    "last": "Ogundare"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Antonio"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Owiafe"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Worwui"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Greenwood"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Alderson"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Traskine"
                },
                {
                    "first": "V.",
                    "initial": "V.",
                    "last": "Verlant"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Dobbelaere"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Borys"
                }
            ],
            "doi": "10.1080/21645515.2015.1111496",
            "firstpage": "393",
            "issn": "21645515",
            "lastpage": "402",
            "pmid": "26618243",
            "pub_year": 2016,
            "title": "Reactogenicity, safety and immunogenicity of a protein-based pneumococcal vaccine in Gambian children aged 2\u20134\u00a0years: A phase II randomized study",
            "volume": "12"
        },
        "b0070": null,
        "b0075": {
            "authors": [
                {
                    "first": "R. A.",
                    "initial": "R.A.",
                    "last": "Hirst"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Kadioglu"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "O'Callaghan"
                },
                {
                    "first": "P. W.",
                    "initial": "P.W.",
                    "last": "Andrew"
                }
            ],
            "doi": "10.1111/j.1365-2249.2004.02611.x",
            "firstpage": "195",
            "issn": "00099104",
            "lastpage": "201",
            "pmid": "15498026",
            "pub_year": 2004,
            "title": "The role of pneumolysin in pneumococcal pneumonia and meningitis",
            "volume": "138"
        },
        "b0080": {
            "authors": [
                {
                    "first": "Charles D.",
                    "initial": "C.D.",
                    "last": "Plumptre"
                },
                {
                    "first": "Abiodun D.",
                    "initial": "A.D.",
                    "last": "Ogunniyi"
                },
                {
                    "first": "James C.",
                    "initial": "J.C.",
                    "last": "Paton"
                }
            ],
            "doi": "10.1016/j.tim.2012.06.004",
            "firstpage": "485",
            "issn": "0966842X",
            "lastpage": "493",
            "pmid": "22819099",
            "pub_year": 2012,
            "title": "Polyhistidine triad proteins of pathogenic streptococci",
            "volume": "20"
        },
        "b0085": {
            "authors": [
                {
                    "first": "J. E.",
                    "initial": "J.E.",
                    "last": "Adamou"
                },
                {
                    "first": "J. H.",
                    "initial": "J.H.",
                    "last": "Heinrichs"
                },
                {
                    "first": "A. L.",
                    "initial": "A.L.",
                    "last": "Erwin"
                },
                {
                    "first": "W.",
                    "initial": "W.",
                    "last": "Walsh"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Gayle"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Dormitzer"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Dagan"
                },
                {
                    "first": "Y. A.",
                    "initial": "Y.A.",
                    "last": "Brewah"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Barren"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Lathigra"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Langermann"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Koenig"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Johnson"
                }
            ],
            "doi": "10.1128/IAI.69.2.949-958.2001",
            "firstpage": "949",
            "issn": "00199567",
            "lastpage": "958",
            "pmid": "11159990",
            "pub_year": 2001,
            "title": "Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis",
            "volume": "69"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Deno\u00ebl"
                },
                {
                    "first": "Fabrice",
                    "initial": "F.",
                    "last": "Godfroid"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Hermand"
                },
                {
                    "first": "Vincent",
                    "initial": "V.",
                    "last": "Verlant"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Poolman"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.01.085",
            "firstpage": "6451",
            "issn": "0264410X",
            "lastpage": "6453",
            "pmid": "21315695",
            "pub_year": 2011,
            "title": "Combined protective effects of anti-PhtD and anti-pneumococcal polysaccharides",
            "volume": "29"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Mar\u00eda",
                    "initial": "M.",
                    "last": "Del Mar Garc\u00eda-Su\u00e1rez"
                },
                {
                    "first": "Mar\u00eda Dolores",
                    "initial": "M.D.",
                    "last": "Cima-Cabal"
                },
                {
                    "first": "Noelia",
                    "initial": "N.",
                    "last": "Fl\u00f3rez"
                },
                {
                    "first": "Pilar",
                    "initial": "P.",
                    "last": "Garc\u00eda"
                },
                {
                    "first": "Rafael",
                    "initial": "R.",
                    "last": "Cernuda-Cernuda"
                },
                {
                    "first": "Aurora",
                    "initial": "A.",
                    "last": "Astudillo"
                },
                {
                    "first": "Fernando",
                    "initial": "F.",
                    "last": "V\u00e1zquez"
                },
                {
                    "first": "Juan R.",
                    "initial": "J.R.",
                    "last": "De Los Toyos"
                },
                {
                    "first": "F. Javier",
                    "initial": "F.J.",
                    "last": "M\u00e9ndez"
                }
            ],
            "doi": "10.1128/IAI.72.8.4534-4540.2004",
            "firstpage": "4534",
            "issn": "00199567",
            "lastpage": "4540",
            "pmid": "15271913",
            "pub_year": 2004,
            "title": "Protection against pneumococcal pneumonia in mice by monoclonal antibodies to pneumolysin",
            "volume": "72"
        },
        "b0100": {
            "authors": [
                {
                    "first": "Abiodun D.",
                    "initial": "A.D.",
                    "last": "Ogunniyi"
                },
                {
                    "first": "Marcin",
                    "initial": "M.",
                    "last": "Grabowicz"
                },
                {
                    "first": "Layla K.",
                    "initial": "L.K.",
                    "last": "Mahdi"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Cook"
                },
                {
                    "first": "David L.",
                    "initial": "D.L.",
                    "last": "Gordon"
                },
                {
                    "first": "Tania A.",
                    "initial": "T.A.",
                    "last": "Sadlon"
                },
                {
                    "first": "James C.",
                    "initial": "J.C.",
                    "last": "Paton"
                }
            ],
            "doi": "10.1096/fj.08-119537",
            "firstpage": "731",
            "issn": "08926638",
            "lastpage": "738",
            "pmid": "18971260",
            "pub_year": 2009,
            "title": "Pneumococcal histidine triad proteins are regulated by the Zn2+ -dependent repressor AdcR and inhibit complement deposition through the recruitment of complement Factor H",
            "volume": "23"
        },
        "b0105": {
            "authors": [
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Deno\u00ebl"
                },
                {
                    "first": "Mario T.",
                    "initial": "M.T.",
                    "last": "Philipp"
                },
                {
                    "first": "Lara",
                    "initial": "L.",
                    "last": "Doyle"
                },
                {
                    "first": "Dale",
                    "initial": "D.",
                    "last": "Martin"
                },
                {
                    "first": "Georges",
                    "initial": "G.",
                    "last": "Carletti"
                },
                {
                    "first": "Jan T.",
                    "initial": "J.T.",
                    "last": "Poolman"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.05.051",
            "firstpage": "5495",
            "issn": "0264410X",
            "lastpage": "5501",
            "pmid": "21624422",
            "pub_year": 2011,
            "title": "A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae",
            "volume": "29"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Fabrice",
                    "initial": "F.",
                    "last": "Godfroid"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Hermand"
                },
                {
                    "first": "Vincent",
                    "initial": "V.",
                    "last": "Verlant"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Deno\u00ebl"
                },
                {
                    "first": "Jan T.",
                    "initial": "J.T.",
                    "last": "Poolman"
                }
            ],
            "doi": "10.1128/IAI.00378-10",
            "firstpage": "238",
            "issn": "00199567",
            "lastpage": "245",
            "pmid": "20956575",
            "pub_year": 2011,
            "title": "Preclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens",
            "volume": "79"
        },
        "b0115": {
            "authors": [
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Hermand"
                },
                {
                    "first": "Annick",
                    "initial": "A.",
                    "last": "Vandercammen"
                },
                {
                    "first": "Emmanuel",
                    "initial": "E.",
                    "last": "Mertens"
                },
                {
                    "first": "Emmanuel",
                    "initial": "E.",
                    "last": "Di Paolo"
                },
                {
                    "first": "Vincent",
                    "initial": "V.",
                    "last": "Verlant"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Deno\u00ebl"
                },
                {
                    "first": "Fabrice",
                    "initial": "F.",
                    "last": "Godfroid"
                }
            ],
            "doi": "10.1080/21645515.2016.1234553",
            "firstpage": "220",
            "issn": "21645515",
            "lastpage": "228",
            "pmid": "27768518",
            "pub_year": 2017,
            "title": "Preclinical evaluation of a chemically detoxified pneumolysin as pneumococcal vaccine antigen",
            "volume": "13"
        },
        "b0120": {
            "authors": [
                {
                    "first": "Aderonke",
                    "initial": "A.",
                    "last": "Odutola"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "Antonio"
                },
                {
                    "first": "Olumuyiwa",
                    "initial": "O.",
                    "last": "Owolabi"
                },
                {
                    "first": "Abdoulie",
                    "initial": "A.",
                    "last": "Bojang"
                },
                {
                    "first": "Ebenezer",
                    "initial": "E.",
                    "last": "Foster-Nyarko"
                },
                {
                    "first": "Simon",
                    "initial": "S.",
                    "last": "Donkor"
                },
                {
                    "first": "Ifedayo",
                    "initial": "I.",
                    "last": "Adetifa"
                },
                {
                    "first": "Sylvia",
                    "initial": "S.",
                    "last": "Taylor"
                },
                {
                    "first": "Christian",
                    "initial": "C.",
                    "last": "Bottomley"
                },
                {
                    "first": "Brian",
                    "initial": "B.",
                    "last": "Greenwood"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "Ota"
                }
            ],
            "doi": "10.1371/journal.pone.0075558",
            "issn": "19326203",
            "pmid": "24086570",
            "pub_year": 2013,
            "title": "Comparison of the Prevalence of Common Bacterial Pathogens in the Oropharynx and Nasopharynx of Gambian Infants",
            "volume": "8"
        },
        "b0125": null,
        "b0130": {
            "authors": [
                {
                    "first": "Emma",
                    "initial": "E.",
                    "last": "Holmlund"
                },
                {
                    "first": "Beatriz",
                    "initial": "B.",
                    "last": "Quiambao"
                },
                {
                    "first": "Jukka",
                    "initial": "J.",
                    "last": "Ollgren"
                },
                {
                    "first": "Teija",
                    "initial": "T.",
                    "last": "Jaakkola"
                },
                {
                    "first": "C\u00e9cile",
                    "initial": "C.",
                    "last": "Neyt"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Poolman"
                },
                {
                    "first": "Hanna",
                    "initial": "H.",
                    "last": "Nohynek"
                },
                {
                    "first": "Helena",
                    "initial": "H.",
                    "last": "K\u00e4yhty"
                }
            ],
            "doi": "10.1128/CVI.00050-09",
            "firstpage": "916",
            "issn": "15566811",
            "lastpage": "923",
            "pmid": "19403781",
            "pub_year": 2009,
            "title": "Antibodies to pneumococcal proteins PhtD, CbpA, and LytC in filipino pregnant women and their infants in relation to pneumococcal carriage",
            "volume": "16"
        },
        "b0135": {
            "authors": [
                {
                    "first": "Emma",
                    "initial": "E.",
                    "last": "Holmlund"
                },
                {
                    "first": "Beatriz",
                    "initial": "B.",
                    "last": "Quiambao"
                },
                {
                    "first": "Jukka",
                    "initial": "J.",
                    "last": "Ollgren"
                },
                {
                    "first": "Hanna",
                    "initial": "H.",
                    "last": "Nohynek"
                },
                {
                    "first": "Helena",
                    "initial": "H.",
                    "last": "K\u00e4yhty"
                }
            ],
            "doi": "10.1016/j.vaccine.2005.07.055",
            "firstpage": "57",
            "issn": "0264410X",
            "lastpage": "65",
            "pmid": "16115703",
            "pub_year": 2006,
            "title": "Development of natural antibodies to pneumococcal surface protein A, pneumococcal surface adhesin a and pneumolysin in Filipino pregnant women and their infants in relation to pneumococcal carriage",
            "volume": "24"
        },
        "b0140": null,
        "b0145": {
            "authors": [
                {
                    "first": "J. E.",
                    "initial": "J.E.",
                    "last": "Alexander"
                },
                {
                    "first": "R. A.",
                    "initial": "R.A.",
                    "last": "Lock"
                },
                {
                    "first": "C. C.A.M.",
                    "initial": "C.C.A.M.",
                    "last": "Peeters"
                },
                {
                    "first": "J. T.",
                    "initial": "J.T.",
                    "last": "Poolman"
                },
                {
                    "first": "P. W.",
                    "initial": "P.W.",
                    "last": "Andrew"
                },
                {
                    "first": "T. J.",
                    "initial": "T.J.",
                    "last": "Mitchell"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Hansman"
                },
                {
                    "first": "J. C.",
                    "initial": "J.C.",
                    "last": "Paton"
                }
            ],
            "firstpage": "5683",
            "issn": "00199567",
            "lastpage": "5688",
            "pmid": "7960154",
            "pub_year": 1994,
            "title": "Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae",
            "volume": "62"
        },
        "b0150": {
            "authors": [
                {
                    "first": "Ravinder",
                    "initial": "R.",
                    "last": "Kaur"
                },
                {
                    "first": "Naveen",
                    "initial": "N.",
                    "last": "Surendran"
                },
                {
                    "first": "Martina",
                    "initial": "M.",
                    "last": "Ochs"
                },
                {
                    "first": "Michael E.",
                    "initial": "M.E.",
                    "last": "Pichichero"
                }
            ],
            "doi": "10.1128/IAI.02124-14",
            "firstpage": "5069",
            "issn": "00199567",
            "lastpage": "5075",
            "pmid": "25245804",
            "pub_year": 2014,
            "title": "Human antibodies to PhtD, PcpA, and ply reduce adherence to human lung epithelial cells and murine nasopharyngeal colonization by Streptococcus pneumoniae",
            "volume": "82"
        },
        "b0155": {
            "authors": [
                {
                    "first": "M. Nadeem",
                    "initial": "M.N.",
                    "last": "Khan"
                },
                {
                    "first": "Michael E.",
                    "initial": "M.E.",
                    "last": "Pichichero"
                }
            ],
            "doi": "10.4161/21645515.2014.979631",
            "firstpage": "3688",
            "issn": "21645515",
            "lastpage": "3699",
            "pmid": "25668673",
            "pub_year": 2014,
            "title": "The host immune dynamics of pneumococcal colonization: Implications for novel vaccine development",
            "volume": "10"
        },
        "b0160": {
            "authors": [
                {
                    "first": "Thierry",
                    "initial": "T.",
                    "last": "Van Effelterre"
                },
                {
                    "first": "Matthew R.",
                    "initial": "M.R.",
                    "last": "Moore"
                },
                {
                    "first": "Frederik",
                    "initial": "F.",
                    "last": "Fierens"
                },
                {
                    "first": "Cynthia G.",
                    "initial": "C.G.",
                    "last": "Whitney"
                },
                {
                    "first": "Lisa",
                    "initial": "L.",
                    "last": "White"
                },
                {
                    "first": "Stephen I.",
                    "initial": "S.I.",
                    "last": "Pelton"
                },
                {
                    "first": "William P.",
                    "initial": "W.P.",
                    "last": "Hausdorff"
                }
            ],
            "doi": "10.1016/j.vaccine.2010.03.030",
            "firstpage": "3650",
            "issn": "0264410X",
            "lastpage": "3660",
            "pmid": "20359560",
            "pub_year": 2010,
            "title": "A dynamic model of pneumococcal infection in the United States: Implications for prevention through vaccination",
            "volume": "28"
        },
        "b0165": {
            "authors": [
                {
                    "first": "Aimee L.",
                    "initial": "A.L.",
                    "last": "Richard"
                },
                {
                    "first": "Steven J.",
                    "initial": "S.J.",
                    "last": "Siegel"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Erikson"
                },
                {
                    "first": "Jeffrey N.",
                    "initial": "J.N.",
                    "last": "Weiser"
                }
            ],
            "doi": "10.1371/journal.ppat.1004339",
            "issn": "15537366",
            "pmid": "25166617",
            "pub_year": 2014,
            "title": "TLR2 Signaling Decreases Transmission of Streptococcus pneumoniae by Limiting Bacterial Shedding in an Infant Mouse Influenza A Co-infection Model",
            "volume": "10"
        }
    },
    "body_text": [
        {
            "endOffset": 27924,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Written informed consent was obtained from a parent or legally-acceptable representative of each infant before any study procedure was performed except when deviations from the informed consent process occurred (Supplementary Text 1).",
            "startOffset": 27690,
            "title": "Study design and participants"
        },
        {
            "endOffset": 35325,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Of 1200 infants enrolled between June 2011 and May 2012, 1152 (96%) completed the study.",
            "startOffset": 35237,
            "title": "Demographics"
        },
        {
            "endOffset": 44375,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 44374,
                    "startOffset": 44370
                }
            },
            "secId": "s0070",
            "sentence": "A study of a trivalent recombinant protein pneumococcal vaccine containing PhtD, PlyD1 (a genetically detoxified Ply), and pneumococcal choline-binding protein A (PcpA) conducted in Bangladesh examined impact on carriage but not as a primary or secondary outcome measure [10].",
            "startOffset": 44099,
            "title": "Discussion"
        },
        {
            "endOffset": 38984,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "No differences in IgG antibody response against Ply or PhtD were observed in subsets of infants with or without pneumococcal NPC before vaccination (Supplementary Fig. S2).",
            "startOffset": 38812,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 41861,
            "parents": [],
            "secId": "s0070",
            "sentence": "We found that the prevalence of pneumococcal carriage, acquisition or clearance of carriage, and pneumococcal load as detected by qPCR and culture were similar across study groups.",
            "startOffset": 41681,
            "title": "Discussion"
        },
        {
            "endOffset": 38419,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "In the control groups, Ply and PhtD antibody GMCs dropped by 42\u201362% between pre-vaccination and age of 5 months, while antibody GMCs increased in the PHiD-CV/dPly/PhtD groups.",
            "startOffset": 38244,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 40454,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "There were few reports of related or grade 3 unsolicited AEs (Supplementary Table S13).",
            "startOffset": 40367,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 42950,
            "parents": [],
            "secId": "s0070",
            "sentence": "Despite the fact that all infants had background antibodies to both proteins before vaccination, robust antibody responses to the Ply component were seen, resulting in substantially higher antibody levels in dPly-containing vaccine recipients compared to control and this difference was sustained up to the age of 12 months.",
            "startOffset": 42626,
            "title": "Discussion"
        },
        {
            "endOffset": 49780,
            "parents": [],
            "secId": "s0075",
            "sentence": "PATH was involved in the study design, data analysis, and data interpretation.",
            "startOffset": 49702,
            "title": "Funding"
        },
        {
            "endOffset": 28242,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Healthy infants aged 8\u201310 weeks were recruited at the health center when brought for immunizations scheduled at two months of age.",
            "startOffset": 28112,
            "title": "Study design and participants"
        },
        {
            "endOffset": 47664,
            "parents": [],
            "secId": "s0070",
            "sentence": "However, our study had some limitations.",
            "startOffset": 47624,
            "title": "Discussion"
        },
        {
            "endOffset": 30716,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0120": {
                    "endOffset": 30563,
                    "startOffset": 30559
                }
            },
            "secId": "s0030",
            "sentence": "Nasopharyngeal swabs were obtained (as described previously [24], apart from the use of flocked nylon-tipped swabs in this study) from all participants at recruitment (age 8\u201310 weeks), and at ages 5, 9, and 12 months.",
            "startOffset": 30499,
            "title": "Study procedures"
        },
        {
            "endOffset": 48528,
            "parents": [],
            "refoffsets": {
                "b0165": {
                    "endOffset": 48485,
                    "startOffset": 48481
                }
            },
            "secId": "s0070",
            "sentence": "No observed effect on carriage prevalence also does not preclude an effect on host-to-host transmission as other mechanisms such as reduction of local inflammation might be involved [33], but this was not evaluated in this study.",
            "startOffset": 48299,
            "title": "Discussion"
        },
        {
            "endOffset": 53070,
            "parents": [],
            "secId": "s0080",
            "sentence": "DB was involved in planning, designing, and reviewing the reported study, analysis plan, interpretation of the results, safety (interaction with and reporting to the Data and Safety Monitoring Board/Independent Data Monitoring Committee), project oversight, and writing the final report.",
            "startOffset": 52783,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 41060,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Six SAEs were fatal (Supplementary Text 4), three in the investigational arms and three in the control groups, with diagnoses of aspiration pneumonia for one case in the PHiD-CV/dPly/PhtD-30 (3 + 0 schedule) group, acute gastroenteritis and sudden infant death syndrome for one case each in the PHiD-CV/dPly/PhtD-30 (2 + 1) group, gastroenteritis for one case in the PHiD-CV (2 + 1) group, and bronchopneumonia and sepsis for one case each in the PCV13 group.",
            "startOffset": 40601,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 37104,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "No differences were observed across groups in pneumococcal load as measured by qPCR (Fig. 3) or semi-quantitative culture assessment (Supplementary Table S3) at any post-vaccination time point.",
            "startOffset": 36911,
            "title": "Serotype/group NPC prevalence and vaccine efficacy"
        },
        {
            "endOffset": 29396,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The primary trial endpoint was the detection of non-10VT serotypes/groups in the nasopharynx at post-immunization visits at ages 5, 9, and 12 months, which was one, five, and eight months after the third vaccine dose in the 3 + 0 groups, and one and five months after the second dose and three months after the booster dose in the 2 + 1 groups.",
            "startOffset": 29052,
            "title": "Study endpoints"
        },
        {
            "endOffset": 46205,
            "parents": [],
            "secId": "s0070",
            "sentence": "It is possible that the characteristics of the induced immune response leading to an impact on carriage in animals differ from those induced in the clinical study.",
            "startOffset": 46042,
            "title": "Discussion"
        },
        {
            "endOffset": 31464,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The adapted broth enrichment method for S. pneumoniae identification, latex agglutination method for serotyping of S. pneumoniae isolates, and bacterial load measurement by quantitative polymerase chain reaction (qPCR) testing and by culture semi-quantitative counts are described in Supplementary Text 2.",
            "startOffset": 31159,
            "title": "Study procedures"
        },
        {
            "endOffset": 31914,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The phtD and ply gene sequencing method for a subset of nasopharyngeal swab isolates containing non-10VT serotypes/serogroups is described in Supplementary Text 2.",
            "startOffset": 31751,
            "title": "Study procedures"
        },
        {
            "endOffset": 36115,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Among PHiD-CV serotypes, serotype 19F (10.5\u201318.0%) followed by 23F (5.0\u201311.0%) had the highest incidence, while the most common vaccine-related serotypes were 6A (13.0\u201322.5%) and 19A (20.5\u201331.5%).",
            "startOffset": 35919,
            "title": "Serotype/group NPC prevalence and vaccine efficacy"
        },
        {
            "endOffset": 33326,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Acquisition at a particular visit was determined when a nasopharyngeal swab was positive for a specific serotype/group after a negative sample for the same infant at the previous visit.",
            "startOffset": 33141,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 50703,
            "parents": [],
            "secId": "s0080",
            "sentence": "MOCO was involved in planning, data collection, review, project oversight on site and was involved in the conception of the study design, trained and supervised clinicians and staff on study procedures, clinically evaluated and investigated the patients, maintained quality assurance over clinical procedures, and supervised the laboratory work.",
            "startOffset": 50358,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 25650,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 25649,
                    "startOffset": 25644
                },
                "b0035": {
                    "endOffset": 25649,
                    "startOffset": 25644
                }
            },
            "secId": "s0005",
            "sentence": "However, use of PCVs is limited by the potential for serotype replacement and high manufacturing costs [3,7].",
            "startOffset": 25541,
            "title": "Introduction"
        },
        {
            "endOffset": 27377,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "A phase 2 randomized, controlled, observer-blind study was conducted at the Fajikunda Health Center situated in a peri-urban area of The Gambia.",
            "startOffset": 27233,
            "title": "Study design and participants"
        },
        {
            "endOffset": 28922,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Infants in the remaining two groups received either PHiD-CV/dPly/PhtD-30 or PHiD-CV at 2, 4, and 9 months of age (2 + 1 infant schedule).",
            "startOffset": 28785,
            "title": "Study design and participants"
        },
        {
            "endOffset": 31647,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Because of technical limitations with the latex agglutination method, results were presented at the serogroup level, except when vaccine or vaccine-related serotypes were determined.",
            "startOffset": 31465,
            "title": "Study procedures"
        },
        {
            "endOffset": 32214,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Antibodies against Ply and PhtD were quantified using GSK in-house individual enzyme-linked immunosorbent assays (ELISAs), with technical cut-off of 12 and 17 ELISA units per mL, respectively.",
            "startOffset": 32022,
            "title": "Study procedures"
        },
        {
            "endOffset": 40366,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Reports of pain at the PHiD-CV/dPly/PhtD vaccine injection site tended to be less frequent than reported for co-administered vaccines (Supplementary Fig. S3).",
            "startOffset": 40208,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 25540,
            "parents": [],
            "refoffsets": {
                "b0030": {
                    "endOffset": 25539,
                    "startOffset": 25536
                }
            },
            "secId": "s0005",
            "sentence": "Immunization with PCVs also has indirect effects, leading to decreases in the incidence of vaccine serotype carriage and disease in non-vaccinated populations [6].",
            "startOffset": 25377,
            "title": "Introduction"
        },
        {
            "endOffset": 31158,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Results for bacteria other than S. pneumoniae will be presented elsewhere.",
            "startOffset": 31084,
            "title": "Study procedures"
        },
        {
            "endOffset": 42626,
            "parents": [],
            "secId": "s0070",
            "sentence": "Also, exploratory analyses showed baseline carriage status of infants and the time of year when infants presented for first vaccination had no clear effects on efficacy against NPC prevalence of non-10VT or any pneumococci.",
            "startOffset": 42403,
            "title": "Discussion"
        },
        {
            "endOffset": 35412,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "The last study visit took place on 18 March 2013.",
            "startOffset": 35363,
            "title": "Demographics"
        },
        {
            "endOffset": 45829,
            "parents": [],
            "refoffsets": {
                "b0150": {
                    "endOffset": 45828,
                    "startOffset": 45824
                }
            },
            "secId": "s0070",
            "sentence": "In contrast, another study reported protection against pneumococcal NPC in mice administered with anti-Ply and anti-PhtD antibodies intravenously [30].",
            "startOffset": 45678,
            "title": "Discussion"
        },
        {
            "endOffset": 33681,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Per episode analyses were conducted for acquisition and clearance, in which each new or cleared serotype/group at a visit was counted as a separate episode, allowing for the carriage of multiple serotypes/groups in an individual.",
            "startOffset": 33452,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 27193,
            "parents": [],
            "secId": "s0005",
            "sentence": "In the second part, we evaluated the impact of the two protein-based pneumococcal vaccine formulations on NPC prevalence of pneumococci, and their reactogenicity, safety, and immunogenicity in infants when given in a three-dose schedule together with routine Expanded Program on Immunization (EPI) vaccines.",
            "startOffset": 26886,
            "title": "Introduction"
        },
        {
            "endOffset": 35715,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "A nasopharyngeal swab sample was cultured for all infants at the first study visit and for at least 99.0% of infants who attended subsequent study visits in each group.",
            "startOffset": 35547,
            "title": "Serotype/group NPC prevalence and vaccine efficacy"
        },
        {
            "endOffset": 53653,
            "parents": [],
            "secId": "s0085",
            "sentence": "MT is employed by the GSK group of companies.",
            "startOffset": 53608,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 29613,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Non-10VT serotypes/groups included any pneumococcal isolates with unknown or determined serotype or serogroup other than those included in the 10-valent PHiD-CV (serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F).",
            "startOffset": 29397,
            "title": "Study endpoints"
        },
        {
            "endOffset": 35494,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Baseline characteristics were similar across the groups (Supplementary Table S1).",
            "startOffset": 35413,
            "title": "Demographics"
        },
        {
            "endOffset": 51751,
            "parents": [],
            "secId": "s0080",
            "sentence": "AW was involved in center coordination, data collection, and quality checks.",
            "startOffset": 51675,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 31750,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Serogroup 6 and serotypes 9A/9V underwent final serotyping by Quellung reaction at Q2 Solutions (USA).",
            "startOffset": 31648,
            "title": "Study procedures"
        },
        {
            "endOffset": 30480,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "All other co-administered injectable vaccines were administered intramuscularly into the left thigh.",
            "startOffset": 30380,
            "title": "Study vaccines"
        },
        {
            "endOffset": 46732,
            "parents": [],
            "refoffsets": {
                "b0155": {
                    "endOffset": 46690,
                    "startOffset": 46686
                }
            },
            "secId": "s0070",
            "sentence": "Immune responses may vary with different adjuvants, particularly stronger induction of T-cell responses, which is thought to be involved in protection against NPC [31], but this was not assessed in this study.",
            "startOffset": 46523,
            "title": "Discussion"
        },
        {
            "endOffset": 37804,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Before vaccination, all infants in all groups had detectable antibody concentrations against Ply and PhtD (above the cut-off values).",
            "startOffset": 37671,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 51042,
            "parents": [],
            "secId": "s0080",
            "sentence": "EOO clinically evaluated and investigated the patients and maintained quality assurance over clinical procedures.",
            "startOffset": 50929,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 31083,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "A study-specific microbiological laboratory standard operating procedure was followed at the Medical Research Council (The Gambia) laboratory for identification of S. pneumoniae, H. influenzae, Staphylococcus aureus, Moraxella catarrhalis, and Group A Streptococcus by standard microbiological culture and biochemical tests, and serotyping of S. pneumoniae isolates.",
            "startOffset": 30717,
            "title": "Study procedures"
        },
        {
            "endOffset": 34531,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Immunogenicity analyses were performed on the according-to-protocol cohort for immunogenicity, defined as vaccinated infants who met all eligibility criteria, complied with all study procedures, and for whom immunogenicity data were available.",
            "startOffset": 34288,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 39402,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Briefly, 18 Ply protein variants were obtained, with variant 1 (100% identity with Ply used for PHiD-CV/dPly/PhtD vaccine) being the most common and present in 62% of samples positive for ply.",
            "startOffset": 39210,
            "title": "Gene sequencing"
        },
        {
            "endOffset": 43104,
            "parents": [],
            "secId": "s0070",
            "sentence": "For PhtD, the magnitude of the antibody response versus control was greatest at 5 months, with diminishing differences between groups at 9 and 12 months.",
            "startOffset": 42951,
            "title": "Discussion"
        },
        {
            "endOffset": 36910,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Acquisition of non-10VT carriage was more frequent than their clearance (Tables 2 and 3), leading to an increase in non-10VT NPC prevalence after primary vaccination (Table 1).",
            "startOffset": 36734,
            "title": "Serotype/group NPC prevalence and vaccine efficacy"
        },
        {
            "endOffset": 44098,
            "parents": [],
            "secId": "s0070",
            "sentence": "There are few reports from other studies that have investigated the impact of protein-based vaccines against pneumococcal NPC prevalence in humans.",
            "startOffset": 43951,
            "title": "Discussion"
        },
        {
            "endOffset": 48935,
            "parents": [],
            "secId": "s0070",
            "sentence": "In conclusion, our study showed that inclusion of pneumococcal proteins in the PHiD-CV/dPly/PhtD investigational vaccine had no impact on pneumococcal NPC prevalence in infants, regardless of protein dose or schedule.",
            "startOffset": 48718,
            "title": "Discussion"
        },
        {
            "endOffset": 25163,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 25162,
                    "startOffset": 25157
                },
                "b0010": {
                    "endOffset": 25162,
                    "startOffset": 25157
                },
                "b0015": {
                    "endOffset": 25162,
                    "startOffset": 25157
                }
            },
            "secId": "s0005",
            "sentence": "Remarkable reductions in the incidence of vaccine serotype invasive pneumococcal disease (IPD) and nasopharyngeal carriage (NPC) prevalence have been recorded in countries that have included a pneumococcal conjugate vaccine (PCV) in their infant immunization program [1\u20133].",
            "startOffset": 24890,
            "title": "Introduction"
        },
        {
            "endOffset": 32287,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Results of other immunogenicity assessments will be described elsewhere.",
            "startOffset": 32215,
            "title": "Study procedures"
        },
        {
            "endOffset": 49348,
            "parents": [],
            "secId": "s0070",
            "sentence": "Another infant trial (ClinicalTrials.gov, NCT01545375) is evaluating protection against acute otitis media in infants receiving dPly and PhtD antigens.",
            "startOffset": 49197,
            "title": "Discussion"
        },
        {
            "endOffset": 40600,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "A total of 21 serious AEs (SAEs) were reported for 19 infants, none of which was assessed by the investigator as causally related to vaccination.",
            "startOffset": 40455,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 28784,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Infants in four groups were vaccinated at 2, 3, and 4 months of age with PHiD-CV/dPly/PhtD-30, PHiD-CV/dPly/PhtD-10, PHiD-CV (Synflorix; GSK, Belgium), or PCV13 (Prevenar 13; Pfizer, USA) (3 + 0 infant schedule) (Fig. 1).",
            "startOffset": 28563,
            "title": "Study design and participants"
        },
        {
            "endOffset": 43776,
            "parents": [],
            "refoffsets": {
                "b0130": {
                    "endOffset": 43775,
                    "startOffset": 43768
                },
                "b0135": {
                    "endOffset": 43775,
                    "startOffset": 43768
                }
            },
            "secId": "s0070",
            "sentence": "In the control groups, antibody GMCs against Ply and PhtD decreased between pre-vaccination and 5 months of age, which is attributed to waning maternal antibodies [26,27].",
            "startOffset": 43605,
            "title": "Discussion"
        },
        {
            "endOffset": 33140,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Percentages of infants with nasopharyngeal swabs positive for S. pneumoniae were calculated with non-adjusted 95% confidence intervals (CIs) at each collection time point, as well as the frequency of acquisition or clearance of serotypes/groups.",
            "startOffset": 32895,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 37654,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Timing of first vaccination according to season also did not alter the vaccine\u2019s effect on carriage prevalence of non-10VT or any pneumococci following vaccination, although seasonal trends were observed (Supplementary Table S6, Fig. S1).",
            "startOffset": 37416,
            "title": "Serotype/group NPC prevalence and vaccine efficacy"
        },
        {
            "endOffset": 35918,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "The most frequent pneumococcal serotypes/groups identified in the nasopharyngeal swab samples across all time points were 15 (22.0\u201332.5%), 19A (20.5\u201331.5%), and 35 (21.5\u201328.0%) (Supplementary Table S2).",
            "startOffset": 35716,
            "title": "Serotype/group NPC prevalence and vaccine efficacy"
        },
        {
            "endOffset": 41680,
            "parents": [],
            "secId": "s0070",
            "sentence": "In this trial setting, we did not show that addition of the pneumococcal proteins dPly and PhtD reduces the prevalence of non-10VT carriage beyond that provided by PHiD-CV, the primary trial endpoint.",
            "startOffset": 41480,
            "title": "Discussion"
        },
        {
            "endOffset": 51618,
            "parents": [],
            "secId": "s0080",
            "sentence": "OTI and OO were involved in clinical evaluation and investigation of the study participants, trained study team staff on procedures and maintained quality assurance over clinical procedures.",
            "startOffset": 51428,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 50357,
            "parents": [],
            "secId": "s0080",
            "sentence": "AO was involved in planning, data collection, site coordination of study, review of the reported study, and trained and supervised clinicians and staff on study procedures, clinically evaluated and investigated the patients, maintained quality assurance over clinical procedures, and drafted the report.",
            "startOffset": 50054,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 48030,
            "parents": [],
            "secId": "s0070",
            "sentence": "Another limitation was that the study was not powered to detect a smaller reduction (below 25%) in non-10VT carriage due to the initial assumption of higher vaccine efficacy against this endpoint.",
            "startOffset": 47834,
            "title": "Discussion"
        },
        {
            "endOffset": 36733,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Similarly, assessment of the numbers of serotypes/groups acquired or cleared at the next visit did not show differences between PHiD-CV/dPly/PhtD and PHiD-CV groups for any serotype/group category (Tables 2 and 3).",
            "startOffset": 36519,
            "title": "Serotype/group NPC prevalence and vaccine efficacy"
        },
        {
            "endOffset": 26317,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 26054,
                    "startOffset": 26050
                },
                "b0080": {
                    "endOffset": 26109,
                    "startOffset": 26105
                },
                "b0085": {
                    "endOffset": 26251,
                    "startOffset": 26244
                },
                "b0090": {
                    "endOffset": 26251,
                    "startOffset": 26244
                },
                "b0095": {
                    "endOffset": 26251,
                    "startOffset": 26244
                },
                "b0100": {
                    "endOffset": 26251,
                    "startOffset": 26244
                },
                "b0105": {
                    "endOffset": 26251,
                    "startOffset": 26244
                },
                "b0110": {
                    "endOffset": 26251,
                    "startOffset": 26244
                },
                "b0115": {
                    "endOffset": 26251,
                    "startOffset": 26244
                }
            },
            "secId": "s0005",
            "sentence": "Two protein candidates, pneumolysin (Ply) [15] and pneumococcal histidine triad protein D (PhtD) [16] (alone or in combination), have shown protection against lethal challenge, septicemia, pneumonia, and NPC prevalence in animal models [17\u201323] and have been selected for clinical development by GSK (Belgium).",
            "startOffset": 26008,
            "title": "Introduction"
        },
        {
            "endOffset": 34975,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "In all exploratory analyses, 95% CIs were used to highlight potential group differences.",
            "startOffset": 34887,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 45197,
            "parents": [],
            "refoffsets": {
                "b0085": {
                    "endOffset": 45083,
                    "startOffset": 45073
                },
                "b0090": {
                    "endOffset": 45083,
                    "startOffset": 45073
                },
                "b0095": {
                    "endOffset": 45083,
                    "startOffset": 45073
                },
                "b0100": {
                    "endOffset": 45083,
                    "startOffset": 45073
                },
                "b0105": {
                    "endOffset": 45083,
                    "startOffset": 45073
                },
                "b0110": {
                    "endOffset": 45083,
                    "startOffset": 45073
                },
                "b0115": {
                    "endOffset": 45083,
                    "startOffset": 45073
                },
                "b0145": {
                    "endOffset": 45083,
                    "startOffset": 45073
                }
            },
            "secId": "s0070",
            "sentence": "In pre-clinical studies, Ply and PhtD, administered either separately or in combination, showed protection against lethal challenge and pneumococcal disease [17\u201323,29] and were therefore considered for vaccine development to provide broader protection against pneumococcal disease.",
            "startOffset": 44916,
            "title": "Discussion"
        },
        {
            "endOffset": 52690,
            "parents": [],
            "secId": "s0080",
            "sentence": "VV contributed to study design, review of the analysis plan, interpretation of the results, and laboratory work supervision.",
            "startOffset": 52566,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 28111,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Interest in participating in the trial was determined from mothers at the time of delivery in the health center or when the infant was brought for first immunizations shortly after birth.",
            "startOffset": 27924,
            "title": "Study design and participants"
        },
        {
            "endOffset": 44916,
            "parents": [],
            "secId": "s0070",
            "sentence": "At sampling points up to 14 days after inoculation, pneumococcal NPC prevalence was reduced by 18\u201336% versus placebo but the group differences were not statistically significant.",
            "startOffset": 44738,
            "title": "Discussion"
        },
        {
            "endOffset": 47058,
            "parents": [],
            "secId": "s0070",
            "sentence": "Moreover, the clinical study was conducted in a setting where the prevalence of pneumococcal NPC among infants is high (pneumococcal and non-10VT NPC prevalence at baseline were 60\u201367% and 55\u201361%, respectively) and therefore most, if not all, infants would have been immunologically primed by prior or ongoing carriage events.",
            "startOffset": 46732,
            "title": "Discussion"
        },
        {
            "endOffset": 30141,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The antigens were adsorbed on aluminum phosphate (vaccine adjuvant; aluminum content 500 \u03bcg).",
            "startOffset": 30048,
            "title": "Study vaccines"
        },
        {
            "endOffset": 52565,
            "parents": [],
            "secId": "s0080",
            "sentence": "KS was involved in the generation of study data and in the interpretation of the results.",
            "startOffset": 52476,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 50928,
            "parents": [],
            "secId": "s0080",
            "sentence": "MAn was involved in planning/design/review of the reported study, interpretation of the results and was involved in planning, designing, and reviewing the reported study, the analysis plan, and interpretation of the results.",
            "startOffset": 50704,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 29793,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "A list of primary and secondary endpoints is provided in Supplementary Text 2.",
            "startOffset": 29715,
            "title": "Study endpoints"
        },
        {
            "endOffset": 51674,
            "parents": [],
            "secId": "s0080",
            "sentence": "PKO, FC, AB, SJ, and ID supervised the laboratory work.",
            "startOffset": 51619,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 27498,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0120": {
                    "endOffset": 27497,
                    "startOffset": 27493
                }
            },
            "secId": "s0015",
            "sentence": "The prevalence of pneumococcal NPC in infants in Fajikunda was known to be high (76% in children aged 15\u201353 weeks) [24].",
            "startOffset": 27378,
            "title": "Study design and participants"
        },
        {
            "endOffset": 46042,
            "parents": [],
            "secId": "s0070",
            "sentence": "Therefore, although pre-clinical assessments suggest that immunization with dPly and PhtD antigens may play a role in protection against NPC, this effect may depend on the route of administration of the antigens.",
            "startOffset": 45830,
            "title": "Discussion"
        },
        {
            "endOffset": 34287,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "qPCR was performed on swabs from 50% of enrolled subjects (100 infants per group; total vaccinated cohort for qPCR analysis).",
            "startOffset": 34162,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 39549,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "High sequence identity (at least 98.5%) was observed, corresponding to a maximum of seven amino acid substitutions among all Ply protein variants.",
            "startOffset": 39403,
            "title": "Gene sequencing"
        },
        {
            "endOffset": 54233,
            "parents": [],
            "secId": "s0090",
            "sentence": "Prevenar 13/Prevnar 13 is a trademark of Pfizer Inc.",
            "startOffset": 54181,
            "title": "Trademark statement"
        },
        {
            "endOffset": 26719,
            "parents": [],
            "refoffsets": {
                "b0055": {
                    "endOffset": 26700,
                    "startOffset": 26696
                },
                "b0060": {
                    "endOffset": 26718,
                    "startOffset": 26714
                }
            },
            "secId": "s0005",
            "sentence": "Investigational vaccines containing dPly (a pneumolysin toxoid) and PhtD (two formulations with either 10 or 30 \u03bcg of each protein) plus 10 serotype-specific polysaccharide conjugates of the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV/dPly/PhtD-10 or PHiD-CV/dPly/PhtD-30) were well tolerated and immunogenic in healthy European adults [11] and toddlers [12].",
            "startOffset": 26318,
            "title": "Introduction"
        },
        {
            "endOffset": 49196,
            "parents": [],
            "secId": "s0070",
            "sentence": "However, the quantitative relationship between the pneumococcal protein-containing vaccines\u2019 impact on NPC prevalence and its impact on pneumococcal disease in humans is yet to be defined, and no effect on carriage does not preclude protection against disease.",
            "startOffset": 48936,
            "title": "Discussion"
        },
        {
            "endOffset": 51122,
            "parents": [],
            "secId": "s0080",
            "sentence": "EOO also participated in the training of some of the staff on study procedures.",
            "startOffset": 51043,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 43604,
            "parents": [],
            "refoffsets": {
                "b0125": {
                    "endOffset": 43603,
                    "startOffset": 43599
                }
            },
            "secId": "s0070",
            "sentence": "This differs from findings in European infants, where superiority with the 30 \u03bcg dose was demonstrated for both proteins one month after three-dose PHiD-CV/dPly/PhtD priming [25].",
            "startOffset": 43425,
            "title": "Discussion"
        },
        {
            "endOffset": 37415,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Exploratory analyses of infants with or without pneumococcal NPC before vaccination did not suggest any differences in prevalence, acquisition, or clearance of non-10VT or any pneumococci between the groups who received the pneumococcal protein-based vaccine and PHiD-CV groups (Supplementary Tables S4 and S5).",
            "startOffset": 37104,
            "title": "Serotype/group NPC prevalence and vaccine efficacy"
        },
        {
            "endOffset": 43950,
            "parents": [],
            "secId": "s0070",
            "sentence": "To our knowledge, this was the first study designed and powered to evaluate the effect of pneumococcal proteins against bacterial carriage in infants as the primary endpoint.",
            "startOffset": 43776,
            "title": "Discussion"
        },
        {
            "endOffset": 27565,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0120": {
                    "endOffset": 27564,
                    "startOffset": 27560
                }
            },
            "secId": "s0015",
            "sentence": "The study area and population have been described previously [24].",
            "startOffset": 27499,
            "title": "Study design and participants"
        },
        {
            "endOffset": 53765,
            "parents": [],
            "secId": "s0085",
            "sentence": "ND, SS, KS, VV, and DB are employed by the GSK group of companies and own shares of the GSK group of companies.",
            "startOffset": 53654,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 46522,
            "parents": [],
            "refoffsets": {
                "b0110": {
                    "endOffset": 46464,
                    "startOffset": 46457
                },
                "b0115": {
                    "endOffset": 46464,
                    "startOffset": 46457
                }
            },
            "secId": "s0070",
            "sentence": "In the pre-clinical studies conducted by our group, E. coli labile toxin was used as adjuvant [22,23], while aluminum phosphate was used in the clinical study.",
            "startOffset": 46363,
            "title": "Discussion"
        },
        {
            "endOffset": 28562,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The methods for pneumococcal vaccine allocation and blinding are described in Supplementary Text 2.",
            "startOffset": 28463,
            "title": "Study design and participants"
        },
        {
            "endOffset": 53542,
            "parents": [],
            "secId": "s0085",
            "sentence": "BK\u2019s institution received grant from Pfizer and PATH outside the submitted work.",
            "startOffset": 53462,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 32895,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The assessment of vaccine efficacy against NPC prevalence was descriptive, with no pre-defined criteria.",
            "startOffset": 32791,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 34886,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Exploratory analyses were conducted in infants with or without pneumococcal NPC at first study visit and in infants grouped according to timing of first study vaccination: August to October 2011, November 2011 to February 2012, and March to May 2012 and July 2011 (rainy season: June to October).",
            "startOffset": 34590,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 52475,
            "parents": [],
            "secId": "s0080",
            "sentence": "SS contributed to the study design, development of the study protocol, development of the analysis plan, interpretation of the results, and laboratory work supervision.",
            "startOffset": 52307,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 38656,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "For the 3 + 0 schedule, the confirmatory objective on dose superiority was not met as the 95% CI for the GMC ratio for antibody responses against both Ply and PhtD after the third vaccine dose did not exclude 1 (Supplementary Table S7).",
            "startOffset": 38420,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 32367,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The reactogenicity and safety assessments are described in Supplementary Text 2.",
            "startOffset": 32287,
            "title": "Study procedures"
        },
        {
            "endOffset": 38047,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "There was a 10- to 18-fold increase in antibody concentrations against Ply from pre-vaccination to last post-vaccination time point in PHiD-CV/dPly/PhtD groups compared with no, or slight, increase in control PHiD-CV or PCV13 groups (Fig. 4).",
            "startOffset": 37805,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 48718,
            "parents": [],
            "secId": "s0070",
            "sentence": "We also did not investigate T-cell responses to the investigational vaccine, which might have enabled us to better understand the nature of the immune response to the pneumococcal proteins.",
            "startOffset": 48529,
            "title": "Discussion"
        },
        {
            "endOffset": 53368,
            "parents": [],
            "secId": "s0085",
            "sentence": "MOCO, MAn, EOO, YS, EFN, PKO, FC, AW, OTI, OO, AB, SJ, ID, and MAl have no conflicts of interest to disclose.",
            "startOffset": 53259,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 26885,
            "parents": [],
            "refoffsets": {
                "b0065": {
                    "endOffset": 26884,
                    "startOffset": 26880
                }
            },
            "secId": "s0005",
            "sentence": "The PHiD-CV/dPly/PhtD-30 formulation was also well tolerated and immunogenic in children aged 2\u20134 years in the first part of this study conducted in The Gambia [13].",
            "startOffset": 26720,
            "title": "Introduction"
        },
        {
            "endOffset": 25376,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 25375,
                    "startOffset": 25370
                },
                "b0025": {
                    "endOffset": 25375,
                    "startOffset": 25370
                }
            },
            "secId": "s0005",
            "sentence": "This was observed in The Gambia following the introduction of the seven-valent PCV (PCV7) into its immunization program in August 2009 followed by replacement with the 13-valent vaccine (PCV13) in May 2011 [4,5].",
            "startOffset": 25164,
            "title": "Introduction"
        },
        {
            "endOffset": 52782,
            "parents": [],
            "secId": "s0080",
            "sentence": "KD was involved in interpretation of the results, coordination, and reporting of the study.",
            "startOffset": 52691,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 30379,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "All pneumococcal vaccines were provided by GSK as mono-dose vials (PHiD-CV and PHiD-CV/dPly/PhtD vaccines) or pre-filled syringes (PCV13) and administered intramuscularly into the right thigh.",
            "startOffset": 30187,
            "title": "Study vaccines"
        },
        {
            "endOffset": 28462,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Eligible participants were randomized (1:1:1:1:1:1) into one of six groups using a computer-generated, block randomization program (block size of six).",
            "startOffset": 28311,
            "title": "Study design and participants"
        },
        {
            "endOffset": 32790,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Vaccine efficacy against NPC prevalence was estimated as 1 minus the relative risk at all post-vaccination time points in the total vaccinated cohort, which included all vaccinated infants.",
            "startOffset": 32601,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 42177,
            "parents": [],
            "secId": "s0070",
            "sentence": "Protein dose superiority (10 or 30 \u03bcg) in terms of immunogenicity for both proteins was not demonstrated.",
            "startOffset": 42072,
            "title": "Discussion"
        },
        {
            "endOffset": 44535,
            "parents": [],
            "refoffsets": {
                "b0140": {
                    "endOffset": 44534,
                    "startOffset": 44530
                }
            },
            "secId": "s0070",
            "sentence": "Initial reports from this study suggested there was no significant difference in carriage prevalence of pneumococci between vaccinated and control groups [28].",
            "startOffset": 44376,
            "title": "Discussion"
        },
        {
            "endOffset": 47185,
            "parents": [],
            "secId": "s0070",
            "sentence": "Thus intramuscular immunization of Gambian infants might have boosted a mucosal immune response primed by natural NP exposure.",
            "startOffset": 47059,
            "title": "Discussion"
        },
        {
            "endOffset": 51427,
            "parents": [],
            "secId": "s0080",
            "sentence": "EFN was involved in the generation, quality control, and interpretation of laboratory results, and laboratory work supervision.",
            "startOffset": 51300,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 40207,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Incidences of solicited and unsolicited adverse events (AEs) were comparable among groups (Supplementary Tables S12 and S13).",
            "startOffset": 40082,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 42402,
            "parents": [],
            "secId": "s0070",
            "sentence": "Gene sequencing results did not suggest that the lack of impact on carriage was due to an absence of ply or phtD genes in S. pneumoniae strains colonizing infants in The Gambia or divergence in Ply or PhtD protein sequences.",
            "startOffset": 42178,
            "title": "Discussion"
        },
        {
            "endOffset": 50032,
            "parents": [],
            "secId": "s0075",
            "sentence": "GlaxoSmithKline Biologicals SA designed the study in collaboration with PATH, London School of Hygiene & Tropical Medicine (LSHTM), and the Medical Research Council (MRC) investigators, and coordinated collection, analysis, and interpretation of data.",
            "startOffset": 49781,
            "title": "Funding"
        },
        {
            "endOffset": 44737,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 44736,
                    "startOffset": 44732
                }
            },
            "secId": "s0070",
            "sentence": "First results are also available from an experimental pneumococcal challenge study of 96 adults in the UK with a protein-based vaccine containing three T-cell antigens, SP0148, SP1912, and SP2108 [14].",
            "startOffset": 44536,
            "title": "Discussion"
        },
        {
            "endOffset": 54180,
            "parents": [],
            "secId": "s0090",
            "sentence": "Synflorix is a trademark of the GSK group of companies.",
            "startOffset": 54125,
            "title": "Trademark statement"
        },
        {
            "endOffset": 39904,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Comparison of protein-based vaccine and control PHiD-CV groups showed PHiD-CV/dPly/PhtD vaccination had no impact on the prevalence of Ply variant 1.",
            "startOffset": 39755,
            "title": "Gene sequencing"
        },
        {
            "endOffset": 51848,
            "parents": [],
            "secId": "s0080",
            "sentence": "BK was involved in project oversight, laboratory work supervision and interpretation of results.",
            "startOffset": 51752,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 33819,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The first secondary (confirmatory) objective was to compare the immunogenicity of protein doses (10 or 30 \u03bcg) given in the 3 + 0 schedule.",
            "startOffset": 33681,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 36366,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "In this study setting, there were no differences in prevalence of non-10VT NPC between groups receiving the pneumococcal protein-based vaccine compared to PHiD-CV control groups, regardless of dose (10 or 30 \u03bcg) or schedule (3 + 0 or 2 + 1) (Table 1).",
            "startOffset": 36115,
            "title": "Serotype/group NPC prevalence and vaccine efficacy"
        },
        {
            "endOffset": 52216,
            "parents": [],
            "secId": "s0080",
            "sentence": "MT was involved in planning, designing, and reviewing the reported study and statistical analysis of the data.",
            "startOffset": 52106,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 53607,
            "parents": [],
            "secId": "s0085",
            "sentence": "BMG reports a grant from PATH to the LSHTM to support the study.",
            "startOffset": 53543,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 45677,
            "parents": [],
            "refoffsets": {
                "b0110": {
                    "endOffset": 45515,
                    "startOffset": 45508
                },
                "b0115": {
                    "endOffset": 45515,
                    "startOffset": 45508
                }
            },
            "secId": "s0070",
            "sentence": "In studies conducted by our group, protection against NPC was observed in mice after immunization with dPly and PhtD only when the proteins were administered via an intranasal route and using Escherichia coli labile toxin as adjuvant [22,23]; there was no protection when the proteins were administered systemically (unpublished data), which is consistent with the results of the present clinical study.",
            "startOffset": 45274,
            "title": "Discussion"
        },
        {
            "endOffset": 52306,
            "parents": [],
            "secId": "s0080",
            "sentence": "ND was involved in the generation of study data and in the interpretation of the results.",
            "startOffset": 52217,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 33451,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Clearance was determined when a swab was negative for a specific serotype/group after a positive swab at the previous visit.",
            "startOffset": 33327,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 27689,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study was conducted in accordance with Good Clinical Practice guidelines and principles of the Declaration of Helsinki.",
            "startOffset": 27566,
            "title": "Study design and participants"
        },
        {
            "endOffset": 41479,
            "parents": [],
            "refoffsets": {
                "b0120": {
                    "endOffset": 41478,
                    "startOffset": 41474
                }
            },
            "secId": "s0070",
            "sentence": "The study was carried out in a community in The Gambia where the prevalence of pneumococcal carriage among infants was known to be very high [24].",
            "startOffset": 41333,
            "title": "Discussion"
        },
        {
            "endOffset": 53861,
            "parents": [],
            "secId": "s0085",
            "sentence": "KD was employed by the GSK group of companies and owns both restricted and unrestricted shares.",
            "startOffset": 53766,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 35214,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The statistical analyses were performed using SAS Drug and Development web portal version 4.3.2 and SAS version 9.3 (SAS Institute, USA).",
            "startOffset": 35077,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 26008,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 26007,
                    "startOffset": 25999
                },
                "b0040": {
                    "endOffset": 26007,
                    "startOffset": 25999
                },
                "b0045": {
                    "endOffset": 26007,
                    "startOffset": 25999
                },
                "b0050": {
                    "endOffset": 26007,
                    "startOffset": 25999
                },
                "b0055": {
                    "endOffset": 26007,
                    "startOffset": 25999
                },
                "b0060": {
                    "endOffset": 26007,
                    "startOffset": 25999
                },
                "b0065": {
                    "endOffset": 26007,
                    "startOffset": 25999
                },
                "b0070": {
                    "endOffset": 26007,
                    "startOffset": 25999
                }
            },
            "secId": "s0005",
            "sentence": "Protein antigens that are conserved across all pneumococcal serotypes have therefore been explored as an alternative and a number, used either alone or in combination with other proteins or polysaccharide conjugates, are being evaluated in clinical trials after demonstration of protection against pneumococcal disease or carriage in animal models [3,8\u201314].",
            "startOffset": 25651,
            "title": "Introduction"
        },
        {
            "endOffset": 29034,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Administration of other vaccines (Supplementary Text 2) was in accordance with the routine Gambian EPI schedule.",
            "startOffset": 28922,
            "title": "Study design and participants"
        },
        {
            "endOffset": 30047,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0065": {
                    "endOffset": 30046,
                    "startOffset": 30042
                }
            },
            "secId": "s0025",
            "sentence": "The investigational pneumococcal vaccines (PHiD-CV/dPly/PhtD-10 or PHiD-CV/dPly/PhtD-30) contained dPly and PhtD at 10 or 30 \u03bcg each, combined with the 10 serotype-specific PHiD-CV polysaccharide conjugates, as described previously [13].",
            "startOffset": 29810,
            "title": "Study vaccines"
        },
        {
            "endOffset": 34162,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Superiority of one formulation over the other was to be demonstrated if the 95% CIs for the antibody geometric mean concentration (GMC) ratios (analysis of covariance model with adjustment for baseline concentrations; pooled variance) between the 30 \u03bcg group and 10 \u03bcg group did not include 1 for antibody responses against both Ply and PhtD.",
            "startOffset": 33820,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 32600,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "A sample size of 200 participants per group allowed detection of 35% reduction in non-10VT carriage prevalence with 82% power, assuming that non-10VT carriage prevalence in the comparator PHiD-CV group was 40%.",
            "startOffset": 32390,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 34589,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Safety analyses were done on the total vaccinated cohort.",
            "startOffset": 34532,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 45273,
            "parents": [],
            "refoffsets": {
                "b0110": {
                    "endOffset": 45272,
                    "startOffset": 45262
                },
                "b0115": {
                    "endOffset": 45272,
                    "startOffset": 45262
                },
                "b0150": {
                    "endOffset": 45272,
                    "startOffset": 45262
                }
            },
            "secId": "s0070",
            "sentence": "They also showed protection against pneumococcal NPC prevalence [22,23,30].",
            "startOffset": 45198,
            "title": "Discussion"
        },
        {
            "endOffset": 32021,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Blood samples for immunogenicity assessments were taken before vaccination and at ages 5, 9, and 12 months.",
            "startOffset": 31914,
            "title": "Study procedures"
        },
        {
            "endOffset": 53239,
            "parents": [],
            "secId": "s0080",
            "sentence": "All authors had full access to all data in the study, contributed to the writing of this report, and had final responsibility for the decision to submit for publication.",
            "startOffset": 53070,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 39624,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "For PhtD, 84 protein sequences were detected, with no clear major variant.",
            "startOffset": 39550,
            "title": "Gene sequencing"
        },
        {
            "endOffset": 46362,
            "parents": [],
            "secId": "s0070",
            "sentence": "As well as the difference in immunization route, this may be due to differences in the adjuvant and/or initial immune status of mice versus Gambian infants.",
            "startOffset": 46206,
            "title": "Discussion"
        },
        {
            "endOffset": 39135,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Among 350 selected NPC isolates containing non-10VT serotypes/groups, 347 were positive for ply and 342 were positive for phtD genes.",
            "startOffset": 39002,
            "title": "Gene sequencing"
        },
        {
            "endOffset": 43225,
            "parents": [],
            "secId": "s0070",
            "sentence": "The fold increase in antibody concentration from pre- to post-vaccination was lower for PhtD than for Ply in all groups.",
            "startOffset": 43105,
            "title": "Discussion"
        },
        {
            "endOffset": 30186,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The control vaccines were PHiD-CV and PCV13.",
            "startOffset": 30142,
            "title": "Study vaccines"
        },
        {
            "endOffset": 47833,
            "parents": [],
            "secId": "s0070",
            "sentence": "Intervals between sampling time points were relatively long and consequently the sensitivity of tests for acquisition or clearance of carriage was probably not optimal.",
            "startOffset": 47665,
            "title": "Discussion"
        },
        {
            "endOffset": 48298,
            "parents": [],
            "refoffsets": {
                "b0160": {
                    "endOffset": 48297,
                    "startOffset": 48293
                }
            },
            "secId": "s0070",
            "sentence": "Reduction of carriage by less than 25% might not preclude efficacy on disease since a dynamic model of pneumococcal infection predicted that 20% effectiveness with PCV7 against vaccine serotype carriage would have a major impact on IPD caused by these serotypes [32].",
            "startOffset": 48031,
            "title": "Discussion"
        },
        {
            "endOffset": 36518,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "The carriage prevalence of non-10VT, any pneumococci, or PHiD-CV serotypes was in the same range among groups at each post-vaccination visit (Table 1).",
            "startOffset": 36367,
            "title": "Serotype/group NPC prevalence and vaccine efficacy"
        },
        {
            "endOffset": 42071,
            "parents": [],
            "secId": "s0070",
            "sentence": "The trial was well powered to detect a statistical difference of 25% between each of the PHiD-CV/dPly/PhtD groups and the PHiD-CV control groups, given the incidence of non-10VT carriage observed in the study.",
            "startOffset": 41862,
            "title": "Discussion"
        },
        {
            "endOffset": 47494,
            "parents": [],
            "secId": "s0070",
            "sentence": "The trial was well conducted with a very high completion rate and detailed evaluation of the impact of the vaccine including measurement of bacterial acquisition, clearance, and load.",
            "startOffset": 47311,
            "title": "Discussion"
        },
        {
            "endOffset": 39209,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Sequencing results are provided in Supplementary Text 3 and Tables S8\u201311.",
            "startOffset": 39136,
            "title": "Gene sequencing"
        },
        {
            "endOffset": 41332,
            "parents": [],
            "secId": "s0070",
            "sentence": "We evaluated the impact of two formulations of an investigational vaccine containing two pneumococcal proteins combined with polysaccharide conjugates of the 10-valent PHiD-CV (PHiD-CV/dPly/PhtD) on NPC prevalence and their immunogenicity and safety in infants.",
            "startOffset": 41071,
            "title": "Discussion"
        },
        {
            "endOffset": 49701,
            "parents": [],
            "secId": "s0075",
            "sentence": "The study was funded by PATH, Seattle, USA, and GlaxoSmithKline Biologicals SA, Belgium.",
            "startOffset": 49613,
            "title": "Funding"
        },
        {
            "endOffset": 54106,
            "parents": [],
            "secId": "s0085",
            "sentence": "The GSK group of companies, MRC, and LSHTM employees report a grant from PATH to their institutions for the conduct of this study.",
            "startOffset": 53976,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 28311,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Inclusion and exclusion criteria are listed in Supplementary Text 2.",
            "startOffset": 28243,
            "title": "Study design and participants"
        },
        {
            "endOffset": 40054,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "There was also no evidence of an impact on average Ply or PhtD sequence identity relative to the amino acid sequences of the proteins in the vaccine.",
            "startOffset": 39905,
            "title": "Gene sequencing"
        },
        {
            "endOffset": 53461,
            "parents": [],
            "secId": "s0085",
            "sentence": "AO received support for study-related travel to conferences from the GSK group of companies.",
            "startOffset": 53369,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 39754,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "All PhtD variants except four (but including the variant used for PHiD-CV/dPly/PhtD vaccines) showed 91.8\u201399.9% protein identity.",
            "startOffset": 39625,
            "title": "Gene sequencing"
        },
        {
            "endOffset": 43424,
            "parents": [],
            "secId": "s0070",
            "sentence": "Anti-Ply GMCs were higher in infants who received the 30 \u03bcg vaccine formulation than in those who received the 10 \u03bcg formulation, whereas the reverse trend was observed for anti-PhtD concentrations.",
            "startOffset": 43226,
            "title": "Discussion"
        },
        {
            "endOffset": 38243,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "The magnitude of increased antibody responses to PhtD was smaller (a 2.3\u20134.0-fold increase in PHiD-CV/dPly/PhtD groups versus a 1.9\u20132.8-fold increase in control PHiD-CV or PCV13 groups) (Fig. 4).",
            "startOffset": 38048,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 47311,
            "parents": [],
            "secId": "s0070",
            "sentence": "This was contrary to the initial unexposed and therefore immunologically na\u00efve status of animals in the pre-clinical studies.",
            "startOffset": 47186,
            "title": "Discussion"
        },
        {
            "endOffset": 49606,
            "parents": [],
            "secId": "s0070",
            "sentence": "If the protein antigens are proven effective in disease protection, their use in combination with conjugates could add value by extending protection to a larger set of pneumococcal serotypes while maintaining the well established effect of the existing PCV.",
            "startOffset": 49349,
            "title": "Discussion"
        },
        {
            "endOffset": 51299,
            "parents": [],
            "secId": "s0080",
            "sentence": "YS trained and supervised clinicians and staff on study procedures and clinically evaluated and investigated patients and maintained quality assurance over clinical procedures.",
            "startOffset": 51123,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 35362,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Participant flow is shown in Fig. 2.",
            "startOffset": 35326,
            "title": "Demographics"
        },
        {
            "endOffset": 53975,
            "parents": [],
            "secId": "s0085",
            "sentence": "VV is the inventor of some pending patents owned by the GSK group of companies in the pneumococcal vaccine field.",
            "startOffset": 53862,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 29714,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The first secondary endpoint was the immune response to Ply and PhtD given at a dose of 10 or 30 \u03bcg.",
            "startOffset": 29614,
            "title": "Study endpoints"
        },
        {
            "endOffset": 35077,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Since there was no adjustment for multiplicity, such differences were to be interpreted with caution.",
            "startOffset": 34976,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 47623,
            "parents": [],
            "secId": "s0070",
            "sentence": "The methodology developed will be of interest to other groups contemplating pneumococcal vaccine trials with NPC as an endpoint.",
            "startOffset": 47495,
            "title": "Discussion"
        },
        {
            "endOffset": 52105,
            "parents": [],
            "secId": "s0080",
            "sentence": "MAl was involved in planning, designing, and reviewing the reported study and interpretation of the results.",
            "startOffset": 51997,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 51996,
            "parents": [],
            "secId": "s0080",
            "sentence": "BMG contributed to the study design, development of the study protocol, analysis plan, interpretation of the results, and writing the final report.",
            "startOffset": 51849,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 38812,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "For antibody responses against Ply, the adjusted GMC was higher for the 30 \u03bcg than the 10 \u03bcg dose while for anti-PhtD responses, the trend was the reverse.",
            "startOffset": 38657,
            "title": "Immunogenicity"
        }
    ],
    "docId": "S0264410X1730405X",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "aaodutola@mrc.gm",
                "first": "Aderonke",
                "initial": "A.",
                "last": "Odutola"
            },
            {
                "email": "otama@who.int",
                "first": "Martin O.C.",
                "initial": "M.O.C.",
                "last": "Ota"
            },
            {
                "email": "mantonio@mrc.gm",
                "first": "Martin",
                "initial": "M.",
                "last": "Antonio"
            },
            {
                "email": "tundeyogundare@yahoo.com",
                "first": "Ezra O.",
                "initial": "E.O.",
                "last": "Ogundare"
            },
            {
                "email": "ysaidu@clintonhealthaccess.org",
                "first": "Yauba",
                "initial": "Y.",
                "last": "Saidu"
            },
            {
                "email": "efosternyarko@mrc.gm",
                "first": "Ebenezer",
                "initial": "E.",
                "last": "Foster-Nyarko"
            },
            {
                "email": "pkowiafe@uhas.edu.gh",
                "first": "Patrick K.",
                "initial": "P.K.",
                "last": "Owiafe"
            },
            {
                "email": "faceesay@mrc.gm",
                "first": "Fatima",
                "initial": "F.",
                "last": "Ceesay"
            },
            {
                "email": "aworwui@mrc.gm",
                "first": "Archibald",
                "initial": "A.",
                "last": "Worwui"
            },
            {
                "email": "oidoko@mrc.gm",
                "first": "Olubukola T.",
                "initial": "O.T.",
                "last": "Idoko"
            },
            {
                "email": "oowolabi@mrc.gm",
                "first": "Olumuyiwa",
                "initial": "O.",
                "last": "Owolabi"
            },
            {
                "email": "ambojang@mrc.gm",
                "first": "Abdoulie",
                "initial": "A.",
                "last": "Bojang"
            },
            {
                "email": "shjarju@mrc.gm",
                "first": "Sheikh",
                "initial": "S.",
                "last": "Jarju"
            },
            {
                "email": "idrammeh@mrc.gm",
                "first": "Isatou",
                "initial": "I.",
                "last": "Drammeh"
            },
            {
                "email": "bkampmann@mrc.gm",
                "first": "Beate",
                "initial": "B.",
                "last": "Kampmann"
            },
            {
                "email": "Brian.Greenwood@lshtm.ac.uk",
                "first": "Brian M.",
                "initial": "B.M.",
                "last": "Greenwood"
            },
            {
                "email": "malderson@path.org",
                "first": "Mark",
                "initial": "M.",
                "last": "Alderson"
            },
            {
                "email": "magali.x.traskine@gsk.com",
                "first": "Magali",
                "initial": "M.",
                "last": "Traskine"
            },
            {
                "email": "nathalie.i.devos@gsk.com",
                "first": "Nathalie",
                "initial": "N.",
                "last": "Devos"
            },
            {
                "email": "sonia.j.schoonbroodt@gsk.com",
                "first": "Sonia",
                "initial": "S.",
                "last": "Schoonbroodt"
            },
            {
                "email": "kristien.m.swinnen@gsk.com",
                "first": "Kristien",
                "initial": "K.",
                "last": "Swinnen"
            },
            {
                "email": "vincent.verlant@gsk.com",
                "first": "Vincent",
                "initial": "V.",
                "last": "Verlant"
            },
            {
                "email": "dobbelaerekurt@gmail.com",
                "first": "Kurt",
                "initial": "K.",
                "last": "Dobbelaere"
            },
            {
                "email": "dorota.d.borys@gsk.com",
                "first": "Dorota",
                "initial": "D.",
                "last": "Borys"
            }
        ],
        "doi": "10.1016/j.vaccine.2017.03.071",
        "firstpage": "2531",
        "issn": "0264410X",
        "keywords": [
            "Infant",
            "Nasopharyngeal carriage",
            "Pneumococcal histidine triad protein D",
            "Pneumolysin",
            "Streptococcus pneumoniae",
            "Vaccine efficacy"
        ],
        "lastpage": "2542",
        "openaccess": "Full",
        "pub_year": 2017,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: A phase 2, randomized, controlled, observer-blind study"
    }
}